EX-97.1 9 ikt-ex97_1.htm EX-97.1 EX-97.1

 

展位97.1

Inhibikase Therapeutics公司(以下簡稱「公司」)

補償追回政策:根據多德-法蘭克華爾街改革和消費者保護法案第954節,由交易法第10D節編纂,以及紐約證券交易所上市規則303A-14,本公司於2023年12月1日實施了補償追回政策。該政策要求在公司財務報表發生重大錯誤或未遵守聯邦證券法律的財務報告要求的情況下,追回某些形式的高管薪酬。

生效日期:2023年10月2日

1.
目的公司已經採用了這項政策,以便遵守2010年多德-弗蘭克華爾街改革和消費者保護法的第954條款,並由交易所法第10D條和納斯達克上市規則5608條規定的要求,在發生由發行人的基本財務報表中的重大錯誤或未按照聯邦證券法規的財務報告要求造成的會計重組時,要求收回某些形式的高管薪酬。
2.
管理。 本政策應由董事會或者由董事會指定的薪酬委員會管理,此時本文中對董事會的提及應被視爲對薪酬委員會的提及。
3.
定義。 根據本政策的規定,以下大寫字母的術語應具有以下所列含義。
(a)
感謝表” 應指本文所附的確認表爲 附件 A.
(b)
董事會董事會
(c)
委員會:“ shall mean 美國證券交易所。
(d)
覆蓋的高管「被覆蓋的高管」指公司的現任和前任高管,以及董事會隨時認爲適用本政策的其他員工。根據本政策的定義,高管指的是《證券交易法》第16a-1(f)規則下定義的高管。
(e)
錯誤獲得的賠償“對於與重申有關的每個受覆蓋高管,"超額" 指超過根據重申金額確定而不考慮由受覆蓋高管支付的任何稅額計算得出的激勵報酬金額。
(f)
使擁有公司註冊證券類別10%以上股權的官員、董事或實際股東代表簽署人遞交表格3、4和5(包括修正版及有關聯合遞交協議),符合證券交易法案第16(a)條及其下屬規則規定的要求;股票市場公允價值”是指特定日期普通股每股的最後報告銷售價,或者在該日沒有出售,買價和賣價的平均值,無論哪種情況,都是在主要綜合交易記賬系統中報告的證券上市或交易允許的納斯達克股票市場或任何其他國家證券交易所,或者如果普通股沒有被列出或允許交易,則爲場外市場上買入和賣出的平均高買價和低賣價,由管理人善意選擇的專業做市商提供的收盤買價和賣價的平均值,或由管理人善意選擇的其他來源或資源提供的收盤買價和賣價的平均值。如果相關日期不是交易日,則應根據前一個交易日進行確定。在此使用的術語「交易日」是指發生公開交易的證券而在上述主要綜合記賬系統中報告的日子,或者如果普通股沒有在國家證券交易所上市或允許交易,則爲任何工作日。在所有情況下,「公允市場價值」應根據符合稅收法案409A條要求的方法確定。
(g)
基本報表措施「財務報告度量標準」是指按照編制公司基本報表所採用的會計原則確定和呈現的度量標準,以及完全或部分衍生自此類度量標準的度量標準,包括但不限於公司營運資本的充裕情況。股票價格和總股東回報率也構成「財務報告度量標準」。財務報告度量標準無需呈現在公司的基本報表中,也無需包含在提交給委員會的申報文件中。
(h)
基於激勵的薪酬「獎勵」是指完全或部分基於財務報告指標達成而授予、獲得或獲得的任何補償,包括但不限於現金激勵獎金和股票期權獎勵。獎勵性報酬應被視爲在達到獎勵性報酬獎勵中規定的財務報告指標的財政期間內收到,即使此類獎勵性報酬在該財政期結束後支付或授予。爲避免疑義,獎勵性報酬不包括年薪、基於完成特定服務期間的獎勵,或基於主觀標準、戰略措施或運營措施的獎勵。
(i)
納斯達克資本市場「」指的是納斯達克股票市場有限責任公司。
(j)
政策「應指本補償追回政策,可能會不時修訂或重述。」
(k)
重述「」將意味着公司由於未遵守聯邦證券法規定的任何財務報告要求而進行的基本報表修正,包括爲糾正先前發佈的對先前基本報表重要的錯誤而進行的任何必需的基本報表修正

1

 


 

發佈基本報表,或者如果在當前期間更正錯誤或在當前期間不更正將導致重大錯報。
(l)
重述日期「」應爲董事會、董事會委員會或董事授權採取行動的日期,如果不需要董事會行動,則董事會行動的日期、結論或合理地應當得出結論,公司需要準備調整財務報表或法庭、監管機構或其他合法授權機構指示公司準備重新編制財務報表的日期。
4.
生效日期。 本政策自本政策第一頁上提及的生效日期起生效,並應適用於在該日期之後批准、授予或授予給覆蓋高管的激勵報酬。
5.
範圍。 本政策適用於所有董事會執行人員在以下情況下獲得的基於激勵的薪酬:(i)擔任執行官後,(ii)在基於激勵的薪酬的績效期間內的執行官,(iii)在公司股票被上市交易所或全國證券協會列出時,以及(iv)在重述日期前的三(3)個已完成財政年度期間。除了這最後三(3)個已完成的財政年度外,該政策還適用於由於公司財政年度在這三(3)個已完成的財政年度內或緊隨其後發生變化而導致的任何過渡期,然而,如果公司上一個財政年度結束日期和新財政年度開始日期之間的過渡期跨越九(9)到十二(12)個月,則將被視爲本政策目的的已完成財政年度。爲避免疑問,公司收回錯誤授予的報酬的義務不取決於是否或何時重述財務報表。
6.
恢復。 如果公司需要編制一份重述,公司應儘快地、儘量地收回在重述日期之前三(3)個財政年度內由覆蓋執行人員收到的任何錯誤授予的報酬。對於基於股價或總股東回報的激勵性報酬,董事會應根據重述對激勵性報酬所基於的股價或總股東回報的影響合理估計錯誤授予的報酬金額,公司應記錄這樣的合理估計並向納斯達克提供相關文件。

覆蓋高管的僱傭狀況發生變化,包括退休或僱傭終止,都不會影響公司根據本政策收回基於激勵的薪酬的權利。

董事會應根據其唯一判斷,判斷根據本政策追回任何基於激勵的報酬的方法。這些方法可能包括但不限於:(i) 通過償還直接追回;(ii) 抵扣未來的補償;(iii) 獎勵權益的沒收;(iv) 抵消或取消計劃中的未來獎勵;(v) 遞延補償的沒收(須遵守《內部收入法典》及相關法規);和/或(vi) 董事會批准並且符合適用法律的任何其他追回行動。

7.
Impracticability. The Board shall recover any Erroneously Awarded Compensation in accordance with this Policy unless such recovery would be impracticable, as determined by the Board in accordance with Rule 10D-1 under the Exchange Act and the listing standards of Nasdaq.
8.
No Indemnification. The Company shall not indemnify any current or former Covered Executive against the loss of Erroneously Awarded Compensation, and shall not pay, or reimburse any Covered Executives, for any insurance policy to fund such executive’s potential recovery obligations.
9.
Acknowledgment. Each Covered Executive shall sign and return to the Company, within thirty (30) calendar days following the later of (i) the effective date of this Policy first set forth above or (ii) the date the individual becomes a Covered Executive, the Acknowledgement Form, pursuant to which the Covered Executive agrees to be bound by, and to comply with, the terms and conditions of this Policy.

2

 


 

10.
Amendment and Interpretation. The Board may amend this Policy from time to time in its discretion, and shall amend this Policy as it deems necessary to reflect the regulations adopted by the Commission and to comply with any rules or standards adopted by Nasdaq or such other national securities exchange on which the Company’s securities are then listed. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the Commission and Nasdaq, or such other national securities exchange on which the Company’s securities are then listed.
11.
Other Recoupment Rights. This Policy shall be applied to the fullest extent of the law. The Board may require that any employment agreement, equity award agreement, or similar agreement entered into on or after the effective date shall require a Covered Executive to agree to abide by the terms of this Policy as a condition to the grant of any benefit. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other rights of recoupment or remedies that may be available to the Company pursuant to the terms of any employment agreement, equity award agreement, similar agreement, or policy and any other legal remedies available to the Company.
12.
Successors. This Policy shall be binding and enforceable against all Covered Executives and their administrators, beneficiaries, executors, heirs, or other legal representatives.
13.
Venue. All actions arising out of or relating to this Policy shall be brought and determined exclusively in the Court of Chancery of the State of Delaware or, in the event that such court does not have subject matter jurisdiction over such action, in any state or federal court within the State of Delaware.
14.
Governing Law. This Policy shall be governed by and construed in accordance with the internal laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).

Annex A

INHIBIKASE THERAPEUTICS, INC.

COMPENSATION CLAWBACK POLICY

ACKNOWLEDGEMENT FORM

By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Inhibikase Therapeutics, Inc. (the “Company”) Compensation Clawback Policy (the “Policy”). Capitalized terms used but not defined in this Acknowledgement Form (this “Acknowledgement Form”) shall have the meanings set forth in the Policy.

By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned’s employment with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Incentive-based Compensation subject to recovery under the Policy to the Company to the extent required by, and in a manner consistent with, the Policy.

________________________________

Signature

 

________________________________

Print Name

 

________________________________

Date

3